New Delhi, July 03: The COVID-19 vaccine developed by Bharat Biotech has shown an overall efficacy of 77.8% in the 3 clinical trials on Saturday. The vaccine also showed 65.2% against the Delta Plus variant.
Efficacy analysis demonstrated Covaxin to be 77.8% effective against symptomatic COVID-19 and 93.4% effective against severe symptomatic COVID-19 cases through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group.
Safety analysis demonstrates adverse events reported were similar to placebo, with 12% of subjects experiencing commonly known side effects and less than 0.5% of subjects feeling serious adverse events. Efficacy data also demonstrated 63.6% protection against asymptomatic COVID-19 and 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant.